Adverse Effect of Hydralazine in Patients With Primary Pulmonary Hypertension
- Itzhak Kronzon, MD;
- Murray Cohen, MD;
- Howard E. Winer, MD
Abstract
Hydralazine hydrochloride has been recommended as a treatment for primary pulmonary hypertension. Two patients who were so treated experienced further elevation of the pulmonary artery pressure and clinical deterioration. The mechanism of this adverse effect was a decrease of systemic vascular resistance attended by an increase in cardiac output without a fall in the pulmonary vascular resistance. Hemodynamic monitoring is advised in patients undergoing vasodilator therapy for primary pulmonary hypertension.
(JAMA 1982;247:3112-3114)
Footnotes
-
Reprint requests to New York University Medical Center, 560 First Ave, Suite 2E, New York, NY 10016 (Dr Kronzon).
